These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37258625)

  • 1. Efficacy and safety of sacubitril/allisartan for the treatment of primary hypertension: a phase 2 randomized, double-blind study.
    Zhang J; Zhang W; Yan J; Ge Q; Lu XH; Chen SX; Xu WJ; Li Y; Li JF; He SY; Wang JG
    Hypertens Res; 2023 Aug; 46(8):2024-2032. PubMed ID: 37258625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Sacubitril/Allisartan for the Treatment of Primary Hypertension.
    Zhang W; Zhang J; Yan J; Ge Q; Lu XH; Chen SX; Xu WJ; Sun JC; Li JF; Liu ZC; Wang Q; Zhou XN; Li Y; Wang JG
    JACC Asia; 2024 Sep; 4(9):697-707. PubMed ID: 39371627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study.
    Huo Y; Li W; Webb R; Zhao L; Wang Q; Guo W
    J Clin Hypertens (Greenwich); 2019 Jan; 21(1):67-76. PubMed ID: 30536595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
    Rakugi H; Kario K; Yamaguchi M; Sasajima T; Gotou H; Zhang J
    Hypertens Res; 2022 May; 45(5):824-833. PubMed ID: 35058583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension.
    Supasyndh O; Wang J; Hafeez K; Zhang Y; Zhang J; Rakugi H
    Am J Hypertens; 2017 Nov; 30(12):1163-1169. PubMed ID: 28992296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
    Kario K; Sun N; Chiang FT; Supasyndh O; Baek SH; Inubushi-Molessa A; Zhang Y; Gotou H; Lefkowitz M; Zhang J
    Hypertension; 2014 Apr; 63(4):698-705. PubMed ID: 24446062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk.
    Li Y; Li XH; Huang ZJ; Yang GP; Zhang GG; Zhao SP; Guo Y; Lu SJ; Ma JL; Meng FB; Chen P; Yuan H
    PLoS One; 2015; 10(2):e0117560. PubMed ID: 25693004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy.
    Wang JG; Yukisada K; Sibulo A; Hafeez K; Jia Y; Zhang J
    J Hypertens; 2017 Apr; 35(4):877-885. PubMed ID: 28030431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
    Williams B; Cockcroft JR; Kario K; Zappe DH; Brunel PC; Wang Q; Guo W
    Hypertension; 2017 Mar; 69(3):411-420. PubMed ID: 28093466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study.
    Izzo JL; Zappe DH; Jia Y; Hafeez K; Zhang J
    J Cardiovasc Pharmacol; 2017 Jun; 69(6):374-381. PubMed ID: 28338503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study.
    Kario K; Rakugi H; Yarimizu D; Morita Y; Eguchi S; Iekushi K
    J Am Heart Assoc; 2023 Apr; 12(8):e027612. PubMed ID: 37026551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.
    Cheung DG; Aizenberg D; Gorbunov V; Hafeez K; Chen CW; Zhang J
    J Clin Hypertens (Greenwich); 2018 Jan; 20(1):150-158. PubMed ID: 29338113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension.
    Wang H; Xi Y; Chen Y; Wang L; Yang F; Lu X; Sun N
    Am J Hypertens; 2023 Sep; 36(10):561-567. PubMed ID: 37343187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of angiotensin receptor blockers for nocturnal blood pressure reduction: a systematic review and meta-analysis.
    Liu J; Chen W; Shao S; Chen Y; Wang H; Xi Y; Wang L
    Ann Med; 2024 Dec; 56(1):2362880. PubMed ID: 38830046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension.
    Li W; Gong M; Yu Q; Liu R; Chen K; Lv W; Yao F; Xu Z; Xu Y; Song W; Jiang Y
    J Clin Hypertens (Greenwich); 2022 Apr; 24(4):449-456. PubMed ID: 35253964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    Schmieder RE; Wagner F; Mayr M; Delles C; Ott C; Keicher C; Hrabak-Paar M; Heye T; Aichner S; Khder Y; Yates D; Albrecht D; Langenickel T; Freyhardt P; Janka R; Bremerich J
    Eur Heart J; 2017 Nov; 38(44):3308-3317. PubMed ID: 29029087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension.
    Zhang Y; Zhao X; Huang H; Li M
    Clin Res Cardiol; 2023 Jul; 112(7):855-867. PubMed ID: 36326841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study.
    Chrysant SG
    Clin Drug Investig; 2010; 30(7):473-82. PubMed ID: 20528002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study).
    Chung WB; Ihm SH; Jang SW; Her SH; Park CS; Lee JM; Chang K; Jeon DS; Yoo KD; Seung KB
    Drug Des Devel Ther; 2020; 14():347-360. PubMed ID: 32158190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.